{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216929","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2026-05-11T20:33:41+00:00","discovered_at":"2026-05-11T20:35:00.299842+00:00","generated_at":"2026-05-11T20:40:36.799703+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Catalyst Q1 2026 revenue $149.4M; FIRDAPSE up 18%, AGAMREE up 67% YoY","bullets":["Product revenue net $149.3M for Q1 2026, up 5.6% YoY from $141.4M.","FIRDAPSE net revenue $98.9M (+18% YoY); AGAMREE $36.7M (+67%); FYCOMPA $13.8M (-61%).","GAAP net income $63.7M ($0.52 basic EPS); non-GAAP net income $100.3M ($0.82 basic EPS).","Cash & equivalents $755.9M at March 31, 2026, up from $709.2M; no funded debt.","No forward guidance or updated FY2026 outlook provided in the release."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216929","json":"https://secwatch.observer/filing/0001193125-26-216929.json","markdown":"https://secwatch.observer/filing/0001193125-26-216929.md","text":"https://secwatch.observer/filing/0001193125-26-216929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526216929/0001193125-26-216929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526216929/d845745d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T20:40:36.799703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}